Ocean Biomedical (NASDAQ: OCEA) Announces Share Price Target Increase to $17.63 by Fundamental Research Corp. on Positive Results from Independent Study Showing Glioblastoma Tumor Suppression, Received Patents, and Recent Financing
June 21, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, June 21, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: “OCEA”), a next-generation biopharma company working to accelerate the development and commercialization of...
Clinical Trial Guide Launches online to help patients and caregivers navigate the clinical trial process
April 12, 2022 09:15 ET
|
Clinical Trial Guide
This new resource at clinicaltrialguide.com seeks to transform the way patients and their caregivers understand and navigate the often overly complicated process of clinical trial...
Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech
March 24, 2020 09:00 ET
|
Akers Biosciences Inc.
Established D-Crypt™ platform will be used to develop a proof-of-concept targeting three of the top five viral vaccine protein candidates for CoronavirusCurrent Regulatory environment could lead to...